Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | FLT3 | P36888 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21082573 | 0.86 | KDM4E (0.68) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL3917266 | 0.86 | ALDH1A1 (0.77) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289513 | 0.83 | KDM4E (0.70) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289710 | 0.82 | KDM4E (0.70) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289503 | 0.82 | KDM4E (0.65) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL3912860 | 0.82 | FLT3 (0.68) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289415 | 0.81 | KDM4E (1.00) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289831 | 0.80 | ALDH1A1 (0.78) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL8289829 | 0.80 | FLT3 (0.66) | KDM4EFLT3KMT2AMEN1CYP1A2 | |
| SCHEMBL5459748 | 0.80 | FLT3 (0.70) | KDM4EFLT3KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366540-A1 | MITOFUSIN INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-11-07 | — | — | US | disclosed |
| EP-4444284-A1 | MITOFUSIN INHIBITORS AND USES THEREOF | Albert Einstein College of Medicine (US) | 2024-10-16 | — | — | EP | disclosed |
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023107880-A1 | MITOFUSIN INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107880-A1 | MITOFUSIN INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-06-15 | — | — | WO | disclosed |
| US-10844023-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20190169138-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2019-06-06 | — | — | US | disclosed |
| WO-2018200323-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169138-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | MFN2, FIS1, RHOT2 | KDM4E 4285/4885FLT3 4205/4885KMT2A 4381/4885 |
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | MFN2, FIS1, RHOT2 | KDM4E 4285/4885FLT3 4205/4885KMT2A 4381/4885 |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | MFN2, FIS1, RHOT2 | KDM4E 4285/4885FLT3 4205/4885KMT2A 4381/4885 |
| US-10844023-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | MFN2, FIS1, RHOT2 | KDM4E 4285/4885FLT3 4205/4885KMT2A 4381/4885 |
| US-20240366540-A1 | MITOFUSIN INHIBITORS AND USES THEREOF | TFAM, MFN2, MAVS | KDM4E 3860/4885FLT3 3657/4885KMT2A 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.